{"filing":{"accession_number":"0001193125-26-279788","cik":"0001819133","ticker":"TNGX","company_name":"Tango Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-23","report_date":null,"primary_document":"d79260d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526279788/d79260d8k.htm"},"events":[{"id":13293,"run_id":11797,"accession_number":"0001193125-26-279788","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Robert Azelby as a director of Tango Therapeutics, effective June 19, 2026, to fill a newly created board vacancy. While the disclosure also includes compensatory arrangements (equity awards and retainers), the principal action is the appointment itself. The appointment of an experienced biopharmaceutical executive with 30+ years of industry leadership to the board of a clinical-stage biotech company is material to investors assessing the company's governance and strategic direction.","company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","filing_date":"2026-06-23","form":"8-K","submitted_at":null,"items":[{"id":10396,"accession_number":"0001193125-26-279788","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Robert Azelby as a director of Tango Therapeutics, effective June 19, 2026, to fill a newly created board vacancy. While the disclosure also includes compensatory arrangements (equity awards and retainers), the principal action is the appointment itself. The appointment of an experienced biopharmaceutical executive with 30+ years of industry leadership to the board of a clinical-stage biotech company is material to investors assessing the company's governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T21:20:37.561794+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10396,"accession_number":"0001193125-26-279788","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Robert Azelby as a director of Tango Therapeutics, effective June 19, 2026, to fill a newly created board vacancy. While the disclosure also includes compensatory arrangements (equity awards and retainers), the principal action is the appointment itself. The appointment of an experienced biopharmaceutical executive with 30+ years of industry leadership to the board of a clinical-stage biotech company is material to investors assessing the company's governance and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T21:20:37.561794+00:00","company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","filing_date":"2026-06-23"}]}